Short communicationPlace preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of μ- and κ-opioid agonists
References (21)
- et al.
Characterization of the binding of [3H]SCH 23390, a selective D1 receptor antagonist ligand, in rat striatum
Life Sci.
(1984) - et al.
Heroin reward is dependent on a dopaminergic substrate
Life Sci.
(1981) SCH 23390 the first selective dopamine D1 antagonist
Eur. J. Pharmacol.
(1983)- et al.
[3H]U-69593 a highly selective ligand for the κ-opioid receptor
Eur. J. Pharmacol.
(1985) - et al.
Neuroleptics block the positive reinforcing effects of amphetamine but not of morphine as measured by place conditioning
Pharmacol. Biochem. Behav.
(1985) - et al.
Dopaminergic substrates of cocaine-induced place conditioning
Brain Research
(1986) - et al.
Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens
Pharmacol. Biochem. Behav.
(1980) - et al.
Dopaminergic substrates of amphetamine-induced place preference conditioning
Brain Research
(1982) Motivational properties of opioids
Pharmacol. Biochem. Behav.
(1985)Action of drugs of abuse on brain reward system
Pharmacol. Biochem. Behav.
(1980)
Cited by (162)
Interactions between opioids and stimulants: Behavioral pharmacology of abuse-related effects
2022, Advances in PharmacologyDopaminergic cellular and circuit contributions to kappa opioid receptor mediated aversion
2019, Neurochemistry InternationalDopamine D1 and D3 receptor modulators restore morphine analgesia and prevent opioid preference in a model of neuropathic pain
2019, NeuroscienceCitation Excerpt :Assessment of D1R and reward potential is well established. Our results in a SCI model confirm what was previously observed for D1R antagonists; they block the induction of conditioned place preference for many drugs of abuse including morphine (Shippenberg and Herz, 1987; Acquas et al., 1989; Nakajima and O'Regan, 1991; Acquas and Di Chiara, 1994). Despite, the ability of D1R agonists to block morphine reward being well established, the underlying mechanism for D1R and D3R effects on morphine reward is currently unknown.
Dopamine D1 and D3 receptor polypharmacology as a potential treatment approach for substance use disorder
2018, Neuroscience and Biobehavioral ReviewsUnderstanding opioid reward
2015, Trends in NeurosciencesCitation Excerpt :The canonical model of opioid reward asserts that the critical dopaminergic terminal region is the ventral striatum. Indeed, dopamine D1 receptor antagonists microinjected into the NAc can reduce MOP receptor agonist reinforcement [89]. However, recent evidence suggests that dopamine can be released in the striatum independent of increases in VTA dopamine neuron activity: first, VTA GABA neurons that project to the NAc synapse onto cholinergic interneurons [39]; second, cholinergic interneuron activation in the NAc can stimulate dopamine release through nicotinic acetylcholine receptors on the striatal terminals of dopamine neurons [90,91].